Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

Conclusion: Our results suggest that levocarnitine administration can reduce the dose of ESAs required in patients with renal anemia on hemodialysis and improve the response to ESA therapy.Cardiorenal Med 2017;7:188-197
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research